Oct 19th, 2022
Featured Science for Monday
Today's Featured Science explores HF, COVID-19 science and post PCI/ACS.
FS.04. Emerging Heart Failure Science
Monday, Nov. 7 | 8-9 a.m. | Main Event II
- Safety and Efficacy of Non-Ischemic Hypothermic Machine Perfusion (NIHP) in Human Heart Transplantation With an Ischemic Time of 6-8 Hours
- A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the Beta3lvh Trial (BETA3LVH)
- The Prelieve Trial: Final 1-Year Outcomes of the Prospective Atrial Flow Regulator Study in Heart Failure Patients and Responder Analysis (Prelieve)
- Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The Breast Cancer Exercise Intervention (BREXIT) Study (BREXIT)
- Dissemination of a Decision Support Tool for Left Ventricular Assist Device: How a Majority of United States Programs Implemented I-DECIDE-LVAD Into Standard Patient Evaluations (I-DECIDE-LVAD)
- STRONG-HF: Successful Post-Discharge Management of Heart Failure (STRONG-HF)
FS.05. Evolving Science in COVID-19
Monday, Nov. 7 | 8-9 a.m. | Main Event III
- Anti-C5a Vilobelimab Reduces All-Cause Mortality in Critically Ill COVID-19 Patients and in Those With Comorbid Hypertension: A Phase 3 Randomized Double-Blind, Placebo-Controlled Study (PANAMO)
- A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (FERMIN)
- Impact of Coronavirus Disease-2019 on Participants in Deliver (DELIVER)
- Rare Coding Variants in Cardiomyopathy-Associated Genes Predispose to Severe COVID-19 and Cardiac Injury (COVID-CARDOGEN)
- Prevalence of Myocarditis Among Patients Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection—14 U.S. States, March 2020-May 2022 (COVID-NET)
FS.06. Optimal Management Post PCI/ACS
Monday, Nov. 7 | 9:30-10:30 a.m. | Main Event III
- Long-Term Outcomes of an Invasive Versus Conservative Strategy in Stabilized Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomized Controlled Trial (After Eighty Study)
- Long-Term Follow-Up of Aspirin Versus Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study
- Impact of Ticagrelor With or Without Aspirin on Total and Recurrent Bleeding and Ischemic Events After PCI: Results From the Twilight -Recurrent Events Sub-Study (TWILIGHT)
- Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study (STOP)
FS.07. A Second Look at Practice-Changing Heart Failure Trials
Monday, Nov. 7 | 11 a.m.-Noon Main Event II
- The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial (DELIVER)
- Baseline Characteristics, Outcomes and Treatment Response to Dapagliflozin in Patients Treated With an MRA or ARNI in DELIVER (DELIVER)
- Sex Differences in Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure (DAPA-HF, DELIVER)
- Differences in Clinical Characteristics, Outcomes and Treatment Response to Dapagliflozin Across the Range of Ejection Fraction in Black and White Patients With Heart Failure: A Pooled Analysis of DAPA-HF and DELIVER (DAPA-HF, DELIVER)
- Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black Versus White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program (EMPEROR-Pooled)
- Long-Term Survival After Cardiac Resynchronization in Ambulatory Heart Failure (RAFT)
FS.08. Digital Innovations to Improve CVD
Monday, Nov. 7 | 11 a.m.-Noon | Main Event III
- Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients With Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days (BT001 PIVOTAL)
- A Randomized Controlled Trial of a Remotely Delivered Mobile Health Intervention to Augment Cardiac Rehabilitation: The Virtual AppLication-Supported ENvironment To INcrease Exercise (VALENTINE) Study (The VALENTINE Study)
- Smartphone-Based Cardiovascular Risk Reduction in Breast Cancer Patients [Smart-Breast]: A Randomized Controlled Trial (SMART-BREAST)
- A PRagmatic Trial Of Messaging to Providers About Treatment of HyperLIPIDemia (PROMPT-LIPID)
- Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-Gated Chest Cts to Improve Statin Rates (NOTIFY-1)
FS.09. The Present and Future of Lipid Lowering
Monday, Nov. 7 | 3-4 p.m. | Main Event III
- ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides and Cholesterol in Patients With Mixed Dyslipidemia (ARCHES-2)
- ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum ApolipoproteinC3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia (SHASTA-2)
- Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies (FOURIER-OLE)
- Efficacy and Safety of Twice-Yearly Subcutaneous Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol up to 4 Years-The Orion-3 Trial
- Individual Participant Data Meta-Analysis of New-Onset and Worsening Diabetes Mellitus in Large-Scale Randomized Double-Blind Trials of Statin Therapy